Location History:
- Union, NJ (US) (2019 - 2021)
- Montvale, NJ (US) (2023)
Company Filing History:
4 out of 1,343 
1 out of 49 Years Active: 2019-2025
Title: Drew Dudgeon: Innovator in Antibody Technology
Introduction
Drew Dudgeon is a prominent inventor based in Union, NJ (US), known for his significant contributions to the field of antibody technology. With a total of 5 patents, Dudgeon has made remarkable strides in developing innovative therapeutic solutions for cancer treatment.
Latest Patents
Dudgeon's latest patents include groundbreaking inventions such as anti-PSMA antibodies and bispecific antigen-binding molecules that target prostate-specific membrane antigen (PSMA) and CD3. These inventions provide antibodies that bind to PSMA with high affinity and induce human T cell proliferation. The bispecific antigen-binding molecules are designed to inhibit the growth of prostate tumors expressing PSMA, making them valuable for treating various cancers. Additionally, he has developed therapeutic uses for anti-GITR antibodies, which specifically bind to glucocorticoid-induced tumor necrosis factor receptor (GITR), offering new methods for cancer treatment.
Career Highlights
Throughout his career, Drew Dudgeon has worked with notable companies, including Regeneron Pharmaceuticals, Inc. His work has focused on advancing antibody technology and developing innovative treatments for cancer, showcasing his commitment to improving patient outcomes.
Collaborations
Dudgeon has collaborated with talented individuals such as Jessica Kirshner and Alison Crawford, contributing to the advancement of research and development in the field of immunotherapy.
Conclusion
Drew Dudgeon's innovative work in antibody technology and his dedication to cancer treatment exemplify the impact of inventors in the medical field. His contributions continue to pave the way for new therapeutic approaches that can significantly benefit patients.